Ultragenyx's 'Fall From Grace' — Shares Crash 47%, Hitting A Record Low

Ultragenyx stock crashed Thursday, losing almost half its value, after its experimental Angelman treatment failed in final-phase testing. The post Ultragenyx's 'Fall From Grace' — Shares Crash 47%, Hitting A Record Low appeared first on Investor's Business Daily.